Drug Crisis: What is the Illinois State Doing to Control the Epidemic?

Pre-Conditions for the Growth of Addiction

The United States has experienced an unprecedented surge in drug use disorders, especially involving opioids, over the past two decades. Nationally, drug overdoses have become one of the leading causes of injury-related death, driven largely by prescription opioids, heroin, and synthetic opioids such as fentanyl. In 2021, an estimated 107,891 overdose deaths were recorded across the country, the highest number ever documented in a 12‑month period. Alongside opioids, cannabis (marijuana) remains the most commonly used federally illicit drug, with rising potency and increasing commercialization contributing to more frequent, heavy use in some populations.

The crisis developed through a combination of aggressive opioid marketing, widespread prescribing, and underestimation of addiction risk in the 1990s and 2000s, which normalized long‑term opioid use for chronic pain. As prescription controls tightened, many individuals with opioid use disorder turned to heroin and later to illicitly manufactured fentanyl, which is far more potent and lethal. Structural factors such as economic decline, unemployment, mental health disorders, and lack of access to affordable treatment further amplified vulnerability to addiction. The COVID‑19 pandemic then intensified isolation, stress, and service disruptions, contributing to record overdose deaths in 2020–2021. At the same time, changing marijuana laws and commercialization increased access, raising concerns about dependence and polysubstance use when cannabis is combined with opioids, alcohol, or stimulants.

Social and Economic Impacts

Opioid, marijuana, and other drug addictions together impose a heavy burden on the U.S. healthcare system. High rates of non‑fatal overdoses lead to repeated emergency medical service (EMS) responses, emergency department visits, intensive care admissions, and long‑term treatment for complications such as infections and organ damage. For example, Illinois alone recorded over 21,900 EMS responses to opioid overdoses in 2022, illustrating the scale of acute care needs created by this epidemic in just one state. Overdose deaths and chronic substance use disorders also worsen co‑occurring conditions such as HIV, hepatitis C, and mental health disorders, further increasing costs for Medicaid, private insurers, and public health systems. Marijuana use disorders, while generally less lethal than opioid problems, contribute to psychiatric comorbidities, emergency visits for cannabis‑induced psychosis or anxiety, and developmental impacts when heavy use starts in adolescence, all of which require additional clinical resources.

Beyond healthcare, the drug crisis undermines public safety and economic productivity nationwide. High prevalence of opioid use disorder is associated with increased crime related to drug trafficking, theft, and impaired driving, as well as a heavier workload for law enforcement and courts. Employers face greater absenteeism, workplace accidents, lower productivity, and difficulty maintaining a stable workforce in regions heavily affected by opioid and polysubstance use. Overdose deaths predominantly affecting working‑age adults shrink the labor force and erode local economies, particularly in communities already struggling with deindustrialization or poverty. Families bear significant financial and emotional costs, including lost income, childcare burdens, and intergenerational trauma, reinforcing cycles of disadvantage that can feed future substance use risk.

Federal Countermeasures

The federal government has launched a series of recent, concrete initiatives targeting the opioid and broader drug crisis, including how it intersects with marijuana policy. Below are five of the most current, high‑impact actions.

1. National Drug Control Strategy Emphasizing Harm Reduction (White House ONDCP)

   The Biden–Harris Administration’s most recent National Drug Control Strategy centers harm reduction, treatment access, and evidence‑based prevention as core pillars for responding to the overdose epidemic. The Strategy calls for expanded access to naloxone, fentanyl test strips, and medications for opioid use disorder (MOUD), and for integrating these tools into healthcare, community programs, and the criminal‑legal system. It targets people who use drugs, their families, healthcare providers, and state and local agencies by providing funding and guidance to implement proven interventions. A key focus is reducing overdose deaths involving fentanyl and other synthetic opioids, which now drive the majority of fatalities. By aligning federal funding and policy with harm reduction science, this strategy is intended to save lives in the short term while supporting long‑term recovery and prevention.

2. Post‑Opioid Settlement Investments and Opioid Remediation Funds

   Following large federal and multistate settlements with opioid manufacturers, distributors, and pharmacies, the federal government has coordinated with states to channel billions of dollars into opioid remediation. These funds must generally be used for approved purposes such as evidence‑based treatment, recovery housing, harm reduction, and prevention, rather than for unrelated budget needs. Illinois, for example, established the Illinois Opioid Remediation Advisory Board to plan and monitor how settlement funds support overdose prevention and treatment initiatives. The primary targets are communities hardest hit by opioid overdoses, including rural areas, communities of color, and people leaving jail or prison. By locking in long‑term, dedicated funding streams, these settlements bolster sustained responses beyond short‑term grant cycles.

3. Expansion of Medication for Opioid Use Disorder (MOUD) Access

   Recent federal policy changes have aimed to normalize and expand access to medications such as buprenorphine, methadone, and extended‑release naltrexone for opioid use disorder. Reforms have increased flexibility for prescribing buprenorphine, encouraged integration of MOUD in primary care and emergency departments, and supported MOUD provision in correctional settings. These initiatives target individuals with opioid use disorder, clinicians, hospitals, and justice systems that historically underutilized evidence‑based medications. Research shows that MOUD significantly reduces mortality, relapse, and criminal activity, making its expansion one of the most effective tools to reduce opioid‑related deaths. By removing regulatory and financial barriers, federal agencies are seeking to make MOUD a standard part of care rather than a niche specialty service.

4. Enhanced Data, Surveillance, and Overdose Dashboards

   The federal government has heavily invested in improving real‑time overdose surveillance through the Centers for Disease Control and Prevention (CDC), supporting state‑level dashboards and rapid data reporting. Better data on substances involved in overdoses (including fentanyl and emerging drugs such as xylazine) enables more targeted public health and law‑enforcement responses. These initiatives target state health departments, policymakers, and researchers who rely on accurate, timely numbers to design interventions and evaluate what works. Illinois’ Overdose Data Dashboard, supported within this broader national effort, provides detailed, regularly updated information on fatalities, EMS responses, and demographic patterns. Enhanced surveillance contributes to reducing the crisis by allowing earlier detection of hot spots and faster deployment of resources like naloxone and outreach teams.

5. Shifting Federal Cannabis Policy and Public Health Guidance

   While marijuana policy is evolving, federal agencies have increased focus on understanding and addressing public health risks associated with cannabis, especially in the context of polysubstance use. National research and guidance emphasize monitoring marijuana use disorders, adolescent use, impaired driving, and interactions between cannabis and opioids or other drugs. This work targets state regulators, clinicians, and the public by providing evidence‑based recommendations on potency limits, product labeling, youth prevention, and data collection. Federal review of cannabis scheduling and greater support for research may enable more nuanced regulation that balances therapeutic uses with the need to prevent addiction and mental health harms. In the broader drug crisis, these actions aim to prevent marijuana‑related problems from amplifying opioid and stimulant epidemics.

Illinois Case – The Numbers Speak for Themselves

Illinois illustrates both the severity of the U.S. drug crisis and the potential impact of coordinated state response, as reflected in statewide addiction statistics. After years of rising deaths, Illinois recorded 3,502 overdose deaths from all drugs in 2023, representing an 8.3% decline from 2022 and the first statewide reduction since 2018. Opioid overdose deaths in Illinois fell from 3,261 in 2022 to 2,855 in 2023, a 9.7% decrease, even though synthetic opioids like fentanyl remain involved in the vast majority of fatal overdoses. Despite this progress, overdose mortality in 2022 was still 26 deaths per 100,000 residents, and EMS responded to more than 21,900 opioid overdoses, underscoring that the crisis remains severe. Marijuana use is widespread in Illinois following legalization, and while cannabis alone is rarely implicated in fatal overdoses, it is frequently used alongside alcohol, opioids, or stimulants, complicating prevention and treatment.

Mortality: According to state data, 3,502 people died from drug overdoses in Illinois in 2023, and 2,855 of these deaths were attributed specifically to opioids. Deaths involving synthetic opioids such as fentanyl declined by 9.5% between 2022 and 2023, while deaths involving heroin and natural or semi‑synthetic opioids fell by 21.2% and 17.4%, respectively. Although marijuana does not typically cause fatal overdose in the way opioids do, its widespread availability and use—including in products with high THC concentrations—raises concerns about addiction, impaired driving, and contribution to polysubstance use patterns that can increase overall overdose risk.

State programs: Illinois has implemented a set of coordinated programs and policies to address opioid and broader drug harms.

• Illinois Statewide Overdose Action Plan (SOAP)

  The Statewide Overdose Action Plan, launched in 2022 under Governor JB Pritzker, is Illinois’ central strategic framework to reduce overdose deaths. It focuses on five priority areas: social equity, prevention, treatment and recovery, harm reduction, and justice‑involved populations and public safety. The Plan guides state agencies and partners in targeting high‑burden communities, expanding access to medications for opioid use disorder, and strengthening overdose prevention services across the state.

• Illinois Opioid Action Plan and Governor’s Opioid Prevention and Intervention Task Force

  The Illinois Opioid Action Plan sets out the state’s long‑term approach to the opioid epidemic, including goals to reduce opioid deaths, expand evidence‑based treatment, and improve prescribing practices. It is supported by a Governor’s Task Force that coordinates efforts across public health, healthcare, law enforcement, and community organizations. By aligning policy and funding, this program has helped Illinois deploy interventions such as prescription monitoring, treatment expansion, and overdose education statewide.

• Illinois Prescription Monitoring Program (PMP)

  The Illinois Prescription Monitoring Program tracks controlled substance prescriptions statewide to identify patterns of high‑risk prescribing and potential doctor‑shopping. Healthcare providers can review a patient’s prescription history before issuing new opioid or other controlled substance prescriptions, helping to prevent inappropriate or duplicative prescribing. By reducing excess opioid supply in the community, the PMP aims to lower the number of people who develop opioid use disorder following medical exposure and to curb diversion of pills to illicit markets.

• Statewide 24/7 Helpline for Opioid and Other Substance Use Disorders

  Illinois operates a 24/7 helpline and associated website (helplineil.org) that connect residents to substance use disorder treatment, recovery support, and medications for opioid and alcohol use disorders. The helpline provides confidential, real‑time referrals to services across the state, including for individuals without insurance or in crisis. State officials credit this service as one factor contributing to the recent decline in overdose deaths, by making it easier for people and families to quickly find care and support.

• Naloxone Access, Hospital Take‑Home Programs, and Jail‑Based Treatment

  Illinois has partnered with efforts such as The Naloxone Project to expand hospital‑based take‑home naloxone distribution and reduce stigma around its use. A growing number of hospitals and community organizations now provide free naloxone kits and training so that patients, families, and bystanders can respond rapidly to overdoses. In parallel, the state supports programs delivering medications for opioid use disorder in jails across multiple counties, aiming to reduce overdose risk during and after incarceration, a period associated with high mortality. Together, these interventions directly target people at highest risk of overdose and have likely contributed to the observed decline in deaths.

Approaches in Neighboring Regions

Illinois shares borders with several states confronting similar overdose and substance use challenges. Below are three of the geographically closest states and one key strategy each has adopted. (Descriptions here are based on widely reported approaches and regional best practices.)

• Indiana

  Indiana has expanded statewide naloxone access through programs that distribute free naloxone kits via local health departments, community organizations, and online request portals. The strategy targets people who use drugs, their families, first responders, and community members who may witness an overdose. By normalizing naloxone and making it widely available, Indiana aims to reduce fatal overdoses while individuals are still in the community and before they engage in formal treatment. Coupled with education on recognizing overdoses, the program helps build community‑level capacity to respond quickly to opioid‑related emergencies.

• Wisconsin

  Wisconsin has focused heavily on building out regional hubs for medication‑assisted treatment and integrating treatment into primary care and behavioral health clinics. This strategy targets rural and underserved populations who previously had to travel long distances for opioid use disorder treatment. By embedding treatment in existing healthcare infrastructure, Wisconsin reduces stigma and logistical barriers that keep people from starting and staying in care. The state also provides technical assistance and funding to clinics to cover startup costs and training, aiming to sustain MOUD availability over time.

• Iowa

  Iowa has invested in statewide drug monitoring and data‑driven early‑warning systems to detect overdose trends and emerging substances. This strategy targets public health agencies, law enforcement, and community coalitions by providing timely data to guide where resources should be deployed. When spikes in overdoses or new synthetic drugs are detected, Iowa can rapidly increase outreach, issue public alerts, and coordinate with healthcare providers. By emphasizing surveillance and rapid response, the state seeks to prevent localized outbreaks from escalating into larger waves of fatalities.

Is It Possible to Stop the Crisis? Looking to the Future

Approaches with Strong Potential Effectiveness

• Investment in Evidence‑Based Treatment (Including MOUD)

  Expanding access to medications for opioid use disorder, counseling, and integrated mental health care is among the most effective ways to reduce overdose deaths and support long‑term recovery. When treatment is affordable, low‑barrier, and available in primary care, community clinics, and correctional facilities, more people can enter and remain in care. Sustained investment also allows states to build robust provider networks and specialized programs for youth, pregnant people, and individuals with co‑occurring disorders. Evidence consistently shows that these approaches reduce mortality, relapse, and criminal justice involvement.

• Harm Reduction and Early Intervention

  Harm reduction tools—naloxone, syringe services, drug‑checking technologies, and overdose education—prevent deaths and infections among people who are not yet ready or able to stop using drugs. Early intervention in emergency departments, primary care, and schools can identify risky use before it progresses to severe addiction. When combined, these approaches meet people “where they are” and create pathways into treatment rather than waiting until a crisis occurs. Over time, this reduces both individual harm and population‑level overdose rates.

• Interagency and Cross‑Sector Cooperation

  Cooperation among public health, healthcare, law enforcement, housing, and social service agencies allows for coordinated, data‑driven responses. Task forces and statewide action plans like Illinois’ SOAP help align goals and reduce duplication of effort. Joint initiatives—such as jail‑based treatment linked to community clinics on release—address critical transition points when overdose risk is highest. This integrated approach recognizes addiction as both a health and a social issue, requiring shared responsibility.

• Public Education and Stigma Reduction Campaigns

  Educational campaigns that provide accurate information about overdose risks, safe use, and available help can reduce stigma and encourage people to seek support earlier. Messaging targeting youth can delay initiation of drug use, especially for substances like high‑potency cannabis and non‑medical use of prescription opioids. Campaigns that humanize people with addiction and highlight recovery stories help shift public opinion toward supportive, health‑focused responses. Over time, this can increase community backing for treatment, harm reduction, and supportive housing programs.

• Data‑Driven Regulation of Legal Substances, Including Marijuana

  As marijuana becomes legal in more states, data‑driven regulation—such as potency caps, child‑resistant packaging, and clear labeling of THC content—helps limit harms while allowing legal markets to function. Monitoring cannabis use patterns alongside opioid, alcohol, and stimulant use supports better understanding of polysubstance risks. States can adjust rules as evidence emerges, for example around advertising restrictions or protections for youth. This flexible, evidence‑based approach reduces unintended consequences that could feed into broader addiction and overdose trends.

Approaches with Low Effectiveness or Proven Limitations

• Repressive Measures Alone (Criminalization Without Treatment)

  Strategies that rely primarily on arrest, incarceration, and punitive sanctions for drug use—without access to treatment and harm reduction—have not been shown to sustainably reduce addiction or overdose. Incarceration without MOUD increases the risk of fatal overdose shortly after release, when tolerance is reduced and people return to prior patterns of use. Punitive approaches can also deepen stigma, discourage help‑seeking, and disproportionately impact marginalized communities. Without parallel investments in health services, enforcement alone often shifts rather than solves the problem.

• Unaccompanied Isolation and Abstinence‑Only Models

  Forcing people into isolated, abstinence‑only settings without medications or follow‑up care frequently leads to short‑term cessation followed by relapse and heightened overdose risk. Loss of tolerance during forced abstinence, such as in jail or certain residential facilities, makes any return to use far more dangerous. These approaches may also fail to address underlying issues like trauma, mental illness, and social instability. Without comprehensive aftercare, housing, and employment support, gains made during isolation are rarely sustained.

• Lack of Aftercare and Recovery Supports

  Short treatment episodes without ongoing recovery supports—peer services, housing, employment assistance, and continuing care—have limited long‑term impact. Addiction is a chronic condition, and people frequently cycle in and out of care when aftercare is weak or absent. Without stable housing and social support, individuals are more likely to return to environments that trigger use, increasing relapse and overdose risk. Systems that do not fund or prioritize long‑term recovery infrastructure often see high readmission rates and limited overall progress.

• Policies Ignoring Social Determinants of Health

  Approaches that focus narrowly on individual behavior while ignoring factors such as poverty, unemployment, trauma, and discrimination address only part of the problem. Communities facing chronic economic and social stress are more vulnerable to substance use epidemics and have fewer resources to mount robust responses. Programs that do not include housing, employment, and mental health supports may help individuals temporarily but struggle to change long‑term patterns at the population level. Comprehensive strategies that integrate social determinants are more likely to produce enduring reductions in addiction and overdose.

Conclusions and Recommendations

The drug crisis in the United States—and in Illinois in particular—remains one of the most pressing public health and social challenges of our time. Illinois’ recent decline in overdose deaths shows that coordinated, data‑driven action can save lives and bend the curve of the epidemic. At the same time, persistently high mortality, widespread polysubstance use, and ongoing strain on families and communities demonstrate that there is no quick or simple solution.

• Every state must develop its own combination of policies and programs tailored to its population, geography, and existing systems.
• Core elements of a successful strategy include investment in evidence‑based treatment and harm reduction, strong data systems, and attention to social determinants of health.
• Open dialogue among people with lived experience, communities, clinicians, policymakers, and law enforcement is essential to designing responses that are both effective and just.
• Long‑term, stable funding—such as settlement and remediation funds—should be protected and used exclusively for prevention, treatment, recovery, and harm reduction.

Ultimately, responding to the drug crisis is a matter of public health responsibility: each state may follow its own path, but lasting success always rests on reliable data, honest conversation, and sustained support for people living with addiction and their families.